A Phase 2/3 interventional study of PHH-1V in SARS CoV 2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Hipra Scientific, S.L.U · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.
Among the 401 studies in COVID-19 with a site in Spain, this one is the 94th largest by enrollment of the 254 interventional ones that give a count, is one of 48 that started in 2022, is one of 25 in phase 2/3, and was the 310th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 21 more countries
Ages 18+
PEACHES BIOTECH · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
401 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 84 · Phase 3 90 · Phase 4 14
First in 2015; this study’s year is marked. 48 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 132 across the 254 interventional studies, 600 across the 146 observational. Of the 287 that completed or were terminated, 73 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 401 have an industry lead sponsor. The 10 most frequent:
Hipra Scientific, S.L.U is the lead sponsor of 8 studies on the registry; none are open to participants now.
Hipra Scientific, S.L.U has 8 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
8 of the studies in COVID-19 with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06544395Clinica Gema LeonEfficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae | 2026-12-01 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 401 studies in COVID-19 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in adults with pre-existing immunosuppressive conditions vaccinated against COVID-19
This is a phase IIb/III, open label, single arm, multi-center clinical trial that aims to determine safety, reactogenicity, tolerability and immunogenicity of additional vaccination with a recombinant protein receptor binding domain (RBD) fusion heterodimer candidate against SARS-CoV-2 developed by HIPRA (PHH-1V) in individuals with pre-existing immunosuppressive conditions. In this phase III study, approximately 400 eligible individuals who have received primary vaccination against COVID-19 with 3 doses of mRNA vaccine (or 2 doses plus a documented history of COVID) last dose being administered at least 91 days before day 0 will be included. Individuals recruited in Turkey which received a primary vaccination regimen using a combination of Coronavac and Comirnaty will be allowed to be included. A maximum of 50% of Individuals with history of COVID-19 disease will be allowed to be included if diagnosed at least 91 days prior, passed 30 days from hospital discharge prior to inclusion and provided they are no suffering from long covid (Post-acute COVID-19 syndrome). All participants will receive a single dose of PHH-1V on Day 0 and will be observed for 15 minutes, except for those participants reporting previous mild allergy reactions to vaccination will be observed for 30 minutes.
All participants will be provided with a paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited adverse events will be reported through Day 28. SAEs, AESI and MAAE will be reported during all the study.
On-site follow-up visits will be performed on Days 14, 91, 182 and 365.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intramuscular injection of HIPRA's COVID-19 vaccine, consisting of 40 mcg/dose.
Biological: PHH-1V
COVID-19 Vaccine HIPRA, 40 mcg/dose
Immunogenicity against Omicron, Beta, Delta at Day 0 and Day 14
Changes in neutralising antibodies measured by pseudovirus (or live virus for the HIV cohort\*) neutralization against Omicron, Beta and Delta any other relevant Variants of Concern (VOC) in the epidemiologic moment, at Baseline and at Day 14 after administration of HIPRA's vaccine (PHH-1V).
Time frame: Day 0 and Day 14
Immunogenicity against Omicron, Beta, Delta at Day 91, Day 182 and Day 365
1\. To determine and compare the changes of the immunogenicity measured by pseudovirus (or live virus for the HIV cohort) neutralization against Omicron, Beta and Delta and any other relevant Variants of Concern (VOC) in the epidemiologic moment at Days, 91, 182 and 365, after administration of HIPRA's vaccine (PHH-1V).
Time frame: Day 91, Day 182 and Day 365
Total antibodies
To evaluate the immunogenicity measured by means of total antibody against Receptor Binding Domain of the Spike protein of SARS-CoV-2 quantification, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and at Days 14, 91, 182 and 365 after administration of HIPRA's vaccine (PHH-1V).
Time frame: Day 0, Day 14, Day 91, Day 182, Day 365
Safety and tolerability of the booster vaccine
To assess the safety and tolerability of PHH-1V as an additional dose in adult individuals with pre-existing immunosuppressive conditions
Time frame: Day 0, Day 14, Day 91, Day 182, Day 365
Number of SARS-CoV-2 infections
Number of participants with SARS-CoV-2 infections ≥14 days after PHH-1V administration.
Time frame: Day 0, Day 14, Day 91, Day 182, Day 365
Number of SARS-CoV-2 severe infections (Severe cases are considered as any episode of COVID-19 requiring ≥ 24hrs of hospitalization.)
Number of COVID-19 severe infections ≥14 days after PHH-1V administration.
Time frame: Day 0, Day 14, Day 91, Day 182, Day 365
Celular immunity
Antibody IgG subclasses titre usage and avidity of humoral immunity at Baseline and Days 14, 91, 182 and 365.
Time frame: Day 0, Day 14, Day 91, Day 182, Day 365
T-cell cellullar immunity
T-cell mediated phenotype polyclonality with potential cross-reactivity capacity and gene-expression profiles against the SARS-CoV-2 Spike \& RBD proteins at Baseline and at Days 14, 91, 182 and 365 in a subset of 50% of participants.
Time frame: Day 0, Day 14, Day 91, Day 182, Day 365
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jan 2024, 19 months.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 19 months is above that.
Counting every sponsor, half of 169 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2023 → Jan 2024 and completion Dec 2023 → Jan 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HIPRA COVID-19 vaccine
Hipra Scientific, S.L.U